Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
02 Abril 2024 - 5:00AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, is pleased to announce the
successful conclusion of a series of large non-rodent animal
infection studies, testing antigens from Evaxion’s preclinical
EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).
In the animal studies, the EVX-B1 antigens significantly reduced
disease burden. Currently, the two companies are engaged in
discussions regarding the path forward.
Birgitte Rønø, Chief Scientific Officer at
Evaxion, expresses enthusiasm: “We are very thrilled about the
encouraging data and believe that our EVX-B1 vaccine antigens hold
the potential for efficacy in human trials – a milestone that
previous vaccine attempts have failed to achieve.”
There is no S. aureus vaccine available for
human use. This pathogen can cause infections of multiple organs
and tissues, which can be profoundly severe or even fatal. Most at
risk are individuals with chronic conditions and patients
undergoing surgeries. Also, the presence of antibiotic-resistant S.
aureus is limiting available treatment options. The Centers for
Disease Control and Prevention (CDC) has reported 120,000
bloodstream infections associated with S. aureus in the US
annually.
Three separate studies in large, non-rodent
animals were conducted with the following conclusions:
- The EVX-B1 vaccine antigens
significantly reduced S. aureus bacterial burden in a surgical site
infection model
- Induction of meaningful
antigen-specific antibody titers in all vaccinated animals
- The ability of the antigens to
induce a protective immune response in the animals when being
colonized with S. aureus mimicking the human situation
- Ability of the immune blood to
neutralize clinically relevant S. aureus in a whole blood killing
assay, holding promise for translational assay readout in early
clinical development
About EVX-B1
The EVX-B1 antigens have been designed using
Evaxion’s AI-Immunology™ platform. AI-Immunology™ has enabled the
identification of novel Staphylococcus aureus antigens, paving the
way for developing a vaccine with the potential for broad
protection against clinically relevant S. aureus strains.
About Staphylococcus
aureus
According to the CDC, S. aureus colonizes about
30% of the human population without causing any harm. However, S.
aureus can also cause infections that can be serious or even fatal.
One of the most serious conditions is bacteremia or sepsis, where
the bacteria spread to the bloodstream. This pathogen can also
cause pneumonia, endocarditis and osteomyelitis (infection of the
lung air sacs, heart valves and bone, respectively). Most at risk
are those with chronic conditions such as diabetes, patients in
intensive care units, patients who have undergone certain types of
surgeries and patients with medical devices inserted in their
bodies. The presence of antibiotic-resistant S. aureus,
particularly Methicillin-resistant S. aureus (MRSA),
further limits treatment options. In the US, nearly 120,000
bloodstream infections and 20,000 deaths were associated with S.
aureus in 2017.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio
company based upon its AI platform, AI-Immunology™. Evaxion’s
proprietary and scalable AI prediction models harness the power of
artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and
viral infections. Based upon AI-Immunology™, Evaxion has developed
a clinical-stage oncology pipeline of novel personalized vaccines
and a preclinical infectious disease pipeline in bacterial and
viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients’ lives by providing innovative and
targeted treatment options. For more information about Evaxion and
its groundbreaking AI-Immunology™ platform and vaccine pipeline,
please visit our website.
Forward-Looking
Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The words “target,” “believe,” “expect,”
“hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar meaning
identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various factors, including, but not limited to,
risks related to: our financial condition and need for additional
capital; our development work; cost and success of our product
development activities and preclinical and clinical trials;
commercializing any approved pharmaceutical product developed using
our AI platform technology, including the rate and degree of market
acceptance of our product candidates; our dependence on third
parties including for conduct of clinical testing and product
manufacture; our inability to enter into partnerships; government
regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary shares,
the impact of international economic, political, legal, compliance,
social and business factors, including inflation, and the effects
on our business from the worldwide ongoing COVID-19 pandemic and
the ongoing conflict in the region surrounding Ukraine and Russia
and the Middle East; and other uncertainties affecting our business
operations and financial condition. For a further discussion of
these risks, please refer to the risk factors included in our most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
www.sec.gov. We do not assume any obligation to
update any forward-looking statements except as required by
law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024